The National Agency for Medicines and Medical Devices (NAMMD) hereby renews warnings to patients and the general public concerning purchase of medicinal products over the Internet because of the serious risk of counterfeit products of uncertain origin, composition and safety. The dose could be too high or too low, or the product may be contaminated.

All persons with a medical condition and requiring treatment are advised to see a healthcare professional and purchase medicinal products from authorised sources only.

The NAMMD adheres to the warning by the UK Medicine and Healthcare products Regulatory Agency – MHRA in its press release of 02/03/2015 on GcMAF (Macrophage Activating Factor Globulin component) product:

https://www.gov.uk/government/news/regulator-warns-against-gcmaf-made-in-unlicensed-facility-in-cambridgeshire

This concerns a blood product, claiming to treat a range of conditions including cancer, HIV and autism. People who have bought this product are advised to speak to their doctor.

The MHRA press release refers to findings of an unannounced inspection at a manufacturing site in Milton, Cambridgeshire, concluding on non-compliance with Good Manufacturing Practice (GMP) rules: the originating material (blood plasma) was not suitable for human use, there were concerns over the sterility of the product being manufactured and the equipment being used, as well as concerns that the product may be contaminated.

The GcMAF product labelled "First Immune" has not been granted a marketing authorisation and has not been tested in order to confirm its quality, safety or efficacy.

The MHRA warning also indicates the websites providing for purchase of the GcMAF product:

www.GcMAF.eu
www.immunobiotech.eu
www.immunocentre.eu
www.petgcmaf.com
www.firstimmune.fr
www.firstimmune.de
www.firstimmune.it
www.gcmaf.gr
www.gcmaf.se
www.gcmaf.se

www.gcmaf.ru www.gcmaf.pl

The NAMMD hereby reiterates the primary objective of its work, i.e. protection and promotion of public health.